ADEDOKUN OMONIYI J ET AL: "Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease", GASTROENTEROLOGY, ELSEVIER INC, US, vol. 154, no. 6, 31 May 2018 (2018-05-31), pages 1660 - 1671, XP085387073, ISSN: 0016-5085, DOI: 10.1053/J.GASTRO.2018.01.043 (B1)

US-A1- 2018 252 728 (B1)

ALLOCCA MARIANGELA ET AL: "Can IL-23 be a good target for ulcerative colitis?", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL GASTROENTEROLOGY, vol. 32-33, 1 February 2018 (2018-02-01), US, pages 95 - 102, XP055924957, ISSN: 1521-6918, DOI: 10.1016/j.bpg.2018.05.016 (B1)

ANGELA SCHOCH ET AL: "Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 19, 27 April 2015 (2015-04-27), pages 5997 - 6002, XP055417991, ISSN: 0027-8424, DOI: 10.1073/pnas.1408766112 (B1)

ANONYMOUS: "A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus- CNTO1275SLE2001; Phase 2a AMENDMENT 3 STELARA® (ustekinumab)", JANSSEN RESEARCH & DEVELOPMENT* CLINICAL PROTOCOL, 18 January 2017 (2017-01-18), pages 1 - 148, XP055697697 (B1)

ANONYMOUS: "A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UNIFI)", CLINICAL TRIALS, 13 August 2018 (2018-08-13), pages 1 - 12, XP055697696, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT02407236> [retrieved on 20191219] (B1)

ANONYMOUS: "A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UNIFI)", CLINICAL TRIALS, 13 August 2018 (2018-08-13), pages 1 - 12, XP055697696, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT02407236> [retrieved on 20200525] (B1)

EMA: "Stelara EPAR Report for the ulcerative colitis indication of ustekinumab, 25 July 2019", 25 July 2019 (2019-07-25), pages 1 - 161, XP093048278, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/medicines/human/EPAR/stelara> [retrieved on 20230522] (B1)

GUDJONSSON, J: "Efficacy and Safety of Ustekinumab, A Human Interleukin-12/23 Monoclonal Antibody", THE LANCET, vol. 371, no. 2625, 17 May 2008 (2008-05-17), pages 1 - 3, XP022683389 (B1)

OCHSENKUHN T ET AL: "P759 Ustekinumab as rescue treatment in therapy-refractory or -intolerant ulcerative colitis", JOURNAL OF CROHN'S AND COLITIS, vol. 12, no. 1, 16 January 2018 (2018-01-16), pages s485, XP093029547 (B1)

OCHSENK�HN T ET AL: "P759 Ustekinumab as rescue treatment in therapy-refractory or -intolerant ulcerative colitis; evidence of publication date", JOURNAL OF CROHN'S AND COLITIS, 16 January 2018 (2018-01-16), pages S495 - S495, XP093029824, Retrieved from the Internet <URL:https://academic.oup.com/ecco-jcc/article/12/supplement_1/S495/4808137> [retrieved on 20230308], DOI: 10.1093/ecco-jcc/jjx180.886 (B1)

PANACCIONE REMO ET AL: "Briakinumab for Treatment of Crohn?s Disease : Results of a Randomized Trial", 1 April 2015 (2015-04-01), US, pages 1, XP055924805, ISSN: 1078-0998, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450894/pdf/ibd-21-1329.pdf> DOI: 10.1097/MIB.0000000000000366 (B1)

SANDS BRUCE E. ET AL: "Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis", vol. 381, no. 13, 26 September 2019 (2019-09-26), US, pages 1201 - 1214, XP055825861, ISSN: 0028-4793, Retrieved from the Internet <URL:https://www.nejm.org/doi/pdf/10.1056/NEJMoa1900750?articleTools=true> DOI: 10.1056/NEJMoa1900750 (B1)

US-A1- 2009 181 027 (B1)

ADEDOKUN, OJ ET AL.: "Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients with Crohn's Disease", GASTROENTEROLOGY, vol. 154, no. 6, 1 February 2018 (2018-02-01), pages 1660 - 1671, XP085387073, DOI: 10.1053/j.gastro.2018.01.043 (B1)